Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst [Yahoo! Finance]
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]
Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.